A Wide Range of Cenobamate Doses Linked to Seizure Freedom
Flexible dosing with Xcopri (cenobamate; SK Life Science, Paramus, NJ) may allow for optimal seizure reduction, according to data presented at the American Epilepsy Society (AES) 2024 Annual Meeting. Results from the post-hoc analysis of an open-label, phase 3 study demonstrate that a wide range of Xcopri doses from 12.5 mg/d to 400 mg/d were associated with the initial seizure-free interval experienced by participants who achieved long-term seizure freedom (SF).
The population of the post-hoc efficacy analysis included 240 participants aged 18 to 70 years from 10 US sites with uncontrolled focal seizures who were treated with stable doses of 1 to 3 ASMs. Participants received Xcopri treatment starting at the recommended initial daily dose of 12.5 mg/d and increasing every 2-weeks to the recommended maintenance dose of 200 mg/d. Further increases up to the maximum approved dose of 400 mg/d were permitted during the maintenance period of the study, and adjustments to concomitant ASMs were allowed. Researchers examined the starting dose at the initial seizure-free period for participants who achieved SF for ≥12 months.
- 62 participants (25.8%) had SF for ≥12 months at their last study visit.
- Of these individuals, 35 (56.5%) had an initial seizure-free interval starting at the 12.5 mg/d to 200 mg/d dose range.
The authors presented the following breakdown of the number of participants starting their initial seizure-free interval at each dose range.
- 10 participants at 12.5 mg/d
- 2 particiapnts at 25 mg/d
- 3 participants at 30 mg/d
- 4 participants at 100 mg/d
- 8 participants at 150 mg/d
- 8 participants at 200 mg/d
- 4 participants at 250 mg/d
- 6 participants at 300 mg/d
- 5 participants at 350 mg/d
- 12 participants at 400 mg/d